Denmark
Abzu, founded in 2018, is a pioneering company in the realm of in silico disease understanding and drug design, headquartered in Denmark with offices in Copenhagen and Barcelona. With their slogan, "Abzu is the best in class in silico disease understanding and drug design company," they have positioned themselves prominently in the AI and machine learning industries. Their proprietary technology, the QLattice®, is a focal innovation that drives their unique approach.
With total funding of €13.3M, Abzu's financial backing underscores their robust growth trajectory, including a recent €2.50M grant investment from the European Innovation Council on 15 June 2022. Abzu’s technology has garnered recognition in influential circles, such as Gartner® research, and awards like the 2023 "Best HealthTech" Nordics Award at the Nordic Startup Awards. Their strategic collaborations with pharma, biotech, and research sectors highlight their impactful role in transforming data into actionable healthcare insights.
